These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 31880872)

  • 1. Treatment Strategies for Tardive Dyskinesia.
    Kremens DE
    J Clin Psychiatry; 2019 Dec; 81(1):. PubMed ID: 31880872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current treatment of tardive dyskinesia.
    Margolius A; Fernandez HH
    Parkinsonism Relat Disord; 2019 Feb; 59():155-160. PubMed ID: 30591350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Tardive Dyskinesia.
    Bashir HH; Jankovic J
    Neurol Clin; 2020 May; 38(2):379-396. PubMed ID: 32279716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacotherapy for the treatment of tardive dyskinesia in schizophrenia patients.
    Witter DP; Holbert RC; Suryadevara U
    Expert Opin Pharmacother; 2017 Jul; 18(10):965-972. PubMed ID: 28443349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors.
    Niemann N; Jankovic J
    Drugs; 2018 Apr; 78(5):525-541. PubMed ID: 29484607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tardive dyskinesia: Who gets it and why.
    Frei K
    Parkinsonism Relat Disord; 2019 Feb; 59():151-154. PubMed ID: 30522959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prevention and treatment of tardive dyskinesia caused by antipsychotic drugs].
    Seigneurie AS; Sauvanaud F; Limosin F
    Encephale; 2016 Jun; 42(3):248-54. PubMed ID: 26922134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deutetrabenazine Provides Long-Term Benefit for Tardive Dyskinesia Regardless of Underlying Condition and Dopamine Receptor Antagonist Use: A Post Hoc Analysis of the 3-Year, Open-Label Extension Study.
    Hauser RA; Barkay H; Fernandez HH; Jimenez-Shahed J; Factor SA; Gross N; Marinelli L; Gordon MF; Barash S; Finkbeiner S; Chaijale N; Anderson KE
    J Clin Psychopharmacol; 2024 Jul-Aug 01; 44(4):386-396. PubMed ID: 38901008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-Induced Dyskinesia, Part 2: Treatment of Tardive Dyskinesia.
    Vijayakumar D; Jankovic J
    Drugs; 2016 May; 76(7):779-87. PubMed ID: 27091214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Revisiting Tardive Dyskinesia: Focusing on the Basics of Identification and Treatment.
    Citrome L; Saklad SR
    J Clin Psychiatry; 2020 Feb; 81(2):. PubMed ID: 32078259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antipsychotic-induced Tardive dyskinesia: from biological basis to clinical management.
    Salem H; Pigott T; Zhang XY; Zeni CP; Teixeira AL
    Expert Rev Neurother; 2017 Sep; 17(9):883-894. PubMed ID: 28750568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics of Patients Experiencing Extrapyramidal Symptoms or Other Movement Disorders Related to Dopamine Receptor Blocking Agent Therapy.
    Musco S; Ruekert L; Myers J; Anderson D; Welling M; Cunningham EA
    J Clin Psychopharmacol; 2019; 39(4):336-343. PubMed ID: 31205194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deutetrabenazine in the treatment of tardive dyskinesia.
    Niemann N; Jimenez-Shahed J
    Neurodegener Dis Manag; 2019 Apr; 9(2):59-71. PubMed ID: 30702019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identifying Tardive Dyskinesia: Risk Factors, Functional Impact, and Diagnostic Tools.
    Saklad SR
    J Clin Psychiatry; 2020 Jan; 81(1):. PubMed ID: 31944066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Late-Onset Dyskinesia Occurring During Antipsychotic Treatment for Schizophrenia: Treatments for Tardive Dyskinesia].
    Nomoto M
    Brain Nerve; 2022 May; 74(5):565-570. PubMed ID: 35589648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetics of tardive dyskinesia: Promising leads and ways forward.
    Zai CC; Maes MS; Tiwari AK; Zai GC; Remington G; Kennedy JL
    J Neurol Sci; 2018 Jun; 389():28-34. PubMed ID: 29502799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrative approach for managing tardive dyskinesia: A case report.
    Kulamarva K; Karanth V; Chikkanna U; Bhargav H; Holla B; Ramakrishna KK; Jasti N; Varambally S
    Explore (NY); 2023; 19(6):865-867. PubMed ID: 37217392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Valbenazine in the treatment of tardive dyskinesia.
    Witek N; Comella C
    Neurodegener Dis Manag; 2019 Apr; 9(2):73-81. PubMed ID: 30724115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Valbenazine for the treatment of tardive dyskinesia.
    Seeberger LC; Hauser RA
    Expert Opin Pharmacother; 2017 Aug; 18(12):1279-1287. PubMed ID: 28699794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical risk factors for the development of tardive dyskinesia.
    Solmi M; Pigato G; Kane JM; Correll CU
    J Neurol Sci; 2018 Jun; 389():21-27. PubMed ID: 29439776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.